Skip to main
MYO
MYO logo

Myomo (MYO) Stock Forecast & Price Target

Myomo (MYO) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Myomo Inc has demonstrated a positive trend in its reimbursement pipeline, increasing from 1,389 units in Q4 to 1,611 units in Q1, indicating growing interest and demand for its myoelectric orthosis products. Additionally, the company's strategic focus on expanding its presence within the larger Medicare market, which represents a significant opportunity for revenue growth, is expected to enhance overall financial performance. The recent favorable ruling from CMS that includes the MyoPro under Medicare Part B benefits further broadens the market potential for Myomo, positioning the company advantageously within the healthcare landscape.

Bears say

Myomo Inc. has lowered its 2025 revenue guidance significantly from a range of $50-53 million to $40-42 million, indicating a potentially troubling outlook for future earnings. Additionally, the quality of recent marketing efforts and pipeline conditions has not met expectations, resulting in decreased lead quality and poor pipeline conversions. Furthermore, the company's authorized insurance backlog has decreased from 272 in the previous quarter to 230, reflecting diminishing demand and a concerning trend in operational performance.

Myomo (MYO) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Myomo and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Myomo (MYO) Forecast

Analysts have given Myomo (MYO) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Myomo (MYO) has a Strong Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Myomo (MYO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.